secwatch.observer — SEC 8-K summary
======================================

Issuer:     Senti Biosciences, Inc. (SNTI)
CIK:        0001854270
Form:       8-K
Filed at:   2024-08-13T23:59:59+00:00
Accession:  0001854270-24-000099
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Senti Bio Q2 net loss $11.2M; doses first patients in Phase 1 AML trial
-----------------------------------------------------------------------

- Net loss of $11.2M ($2.45 per share) for Q2 2024; cash and equivalents $15.9M.
- R&D expenses rose to $9.2M (vs $6.9M YoY) on increased manufacturing costs.
- Phase 1 trial of SENTI-202 for AML now dosing; initial efficacy data expected by year-end 2024.
- Received $8M CIRM grant to support SENTI-202 clinical development.
- Regained Nasdaq minimum bid price compliance after 1-for-10 reverse stock split in July 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1854270/000185427024000099/0001854270-24-000099-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1854270/000185427024000099/snti-20240813.htm
  HTML page:      https://secwatch.observer/filing/0001854270-24-000099

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer